[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"symptomatic-heart-failure-with-preserved-ejection-fraction-hfpef\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:symptomatic-heart-failure-with-preserved-ejection-fraction-hfpef":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100577059","phase-2-amber-hfpef-assessment-of-ck-4021586-in-a-multi-center-blinded-evaluation-of-safety-and-tolerability-results-in-hfpef-100577059",false,"NCT06793371","AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-4021586 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction","AMBER-HFpEF","Inclusion Criteria:\n\n* Males and females ≥ 40 years and ≤ 85 years of age at screening.\n* Diagnosed with HF with NYHA functional class II or III.\n* Screening echocardiography with LVEF ≥ 60%.\n* Screening NT-proBNP ≥ 300 pg\u002FmL for participants in sinus rhythm and ≥ 900 pg\u002FmL for participants with comorbid atrial fibrillation or flutter.\n* Body mass index \\\u003C 40 kg\u002Fm2.\n* Participants on beta-blockers, angiotensin-converting enzyme (ACE)\u002Fangiotensin II receptor blocker (ARB) or angiotensin receptor\u002Fneprilysin inhibitor (ARNI), must be on stable doses for more than 30 days prior to screening.\n* Participants on a glucagon-like peptide-1 (GLP-1) agonist must be on a stable dose for more than 24 weeks prior to screening with no anticipated plans to change dose during this study.\n\nExclusion Criteria:\n\n* History or evidence of any other clinically significant disorder, malignancy, active infection, other condition, or disease that, in the opinion of the investigator or the Medical Monitor, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","40 Years","85 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.",[28],"Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)",[30,31,32,33,34,15,35,36,37,38,39],"Symptomatic heart failure with preserved ejection fraction","HFpEF","Heart failure","CK-4021586","CK-586","AMBER","Cardiac myosin inhibitor","CMI","CY 9021","ulacamten","RECRUITING","2026-05-27",{"date":43,"type":44},"2026-05-29","ACTUAL",{"date":46,"type":44},"2025-02-06",{"date":48,"type":22},"2026-09",{"name":50,"class":51},"Cytokinetics","INDUSTRY",25]